Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

Robert Klamroth, Jerzy Windyga, Vlad Radulescu, Peter W. Collins, Oleksandra Stasyshyn, Hishamshah Mohd Ibrahim, Werner Engl, Srilatha D. Tangada, William Savage, Bruce Ewenstein

Blood (2021) 137 (13): 1818–1827.

https://doi.org/10.1182/blood.2020005673

Published: 2021

Includes: Supplemental data

Journal Articles

Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial

Peter W. Collins, Guy Young, Karin Knobe, Faraizah Abdul Karim, Pantep Angchaisuksiri, Claus Banner, Türkiz Gürsel, Johnny Mahlangu, Tadashi Matsushita, Eveline P. Mauser-Bunschoten, Johannes Oldenburg, Christopher E. Walsh, Claude Negrier

Blood (2014) 124 (26): 3880–3886.

https://doi.org/10.1182/blood-2014-05-573055

Published: 2014

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously-Treated Patients with Hemophilia B: Results from an Extension Trial

Guy Young, MD, Peter W. Collins, MD, Ramin Tehranchi, MD, PhD, Ampaiwan Chuansumrit, Hideji Hanabusa, MD, Steven R. Lentz, MD PhD, Johnny N. Mahlangu, MBBCh, MMed, FCPath, Evelien Mauser-Bunschoten, Claude Negrier, Johannes Oldenburg, MD PhD, Turkan Patiroglu, MD, Elena Santagostino, MD PhD, Marek Zak, Fara Abdul Karim

Blood (2014) 124 (21): 2846.

https://doi.org/10.1182/blood.V124.21.2846.2846

Published: 2014

Journal Articles

Systematic Review of the Published Evidence on the Pharmacokinetic Characteristics of Factor VIII and IX Concentrates

Menchen Xi, Tamara Navarro-Ruan, MLIS. MD, Sunil Mammen, Victor S. Blanchette, MD FRCPC, Cedric R. Hermans, MD PhD, Massimo Morfini, MD, Peter W. Collins, MD, Kathelijn Fischer, MD PhD MSC, Ellis J. Neufeld, Guy Young, MD, Kaan Kavakli, MD, Paolo Radossi, MD, Amy Dunn, Lehana Thabane, PhD, Alfonso Iorio, MD PhD

Blood (2014) 124 (21): 2818.

https://doi.org/10.1182/blood.V124.21.2818.2818

Published: 2014

Journal Articles

Towards Successful Implementation of Pharmacokinetic-Guided Prophylactic Dosing of Clotting Factor Concentrate in Hemophilia; The Do’s and Don’ts after Discrete Choice Experiment Analysis

Janske Lock, MD PhDstudent, Esther W. de Bekker-Grob, PhD, Gamze Urhan, MD, Saskia Middeldorp, MD PhD, Marjolein Peters, MD PhD, Karina Meijer, MD PhD, Rienk Y.J. Tamminga, MD PhD, Britta Laros-van Gorkum, MD PhD, Paul Brons, Felix J.M. Van der Meer, MD PhD, Mariette H.E. Driessens, PhD, Peter W. Collins, MD, Karin Fijnvandraat, MD PhD, Frank W.G. Leebeek, MD PhD, Marjon H. Cnossen, MD PhD

Blood (2014) 124 (21): 5038.

https://doi.org/10.1182/blood.V124.21.5038.5038

Published: 2014

Journal Articles

Modeling Minimally-Effective FVIII Trough Levels in Hemophilia a Patients on PK-Guided Prophylaxis

Gerald Spotts, PhD, Steven W. Pipe, MD, Erik Berntorp, MD PhD, Peter W. Collins, MD, Victor S. Blanchette, MD FRCPC, Kathelijn Fischer, MD PhD MSC, MyungShin Oh, Leonard A. Valentino, MD FAAP

Blood (2014) 124 (21): 689.

https://doi.org/10.1182/blood.V124.21.689.689

Published: 2014

Journal Articles

Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011

Peter W. Collins, Benedict P. Palmer, Elizabeth A. Chalmers, Daniel P. Hart, Ri Liesner, Savita Rangarajan, Katherine Talks, Michael Williams, Charles R. M. Hay

Blood (2014) 124 (23): 3389–3397.

https://doi.org/10.1182/blood-2014-07-580498

Published: 2014

Journal Articles

Fibrin-based clot formation as an early and rapid biomarker for progression of postpartum hemorrhage: a prospective study

Peter W. Collins, Graeme Lilley, Daniel Bruynseels, David Burkett-St. Laurent, Rebecca Cannings-John, Elizabeth Precious, Vincent Hamlyn, Julia Sanders, Raza Alikhan, Rachel Rayment, Alexandra Rees, Abigail Kaye, Judith E. Hall, Shantini Paranjothy, Andrew Weeks, Rachel E. Collis

Blood (2014) 124 (11): 1727–1736.

https://doi.org/10.1182/blood-2014-04-567891

Published: 2014

Includes: Supplemental data

Journal Articles

Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects

Jacqueline Stockley, Neil V. Morgan, Danai Bem, Gillian C. Lowe, Marie Lordkipanidzé, Ban Dawood, Michael A. Simpson, Kirsty Macfarlane, Kevin Horner, Vincenzo C. Leo, Katherine Talks, Jayashree Motwani, Jonathan T. Wilde, Peter W. Collins, Michael Makris, Steve P. Watson, Martina E. Daly

Blood (2013) 122 (25): 4090–4093.

https://doi.org/10.1182/blood-2013-06-506873

Published: 2013

Includes: Supplemental data

Journal Articles

Both TMEM16F-dependent and TMEM16F-independent pathways contribute to phosphatidylserine exposure in platelet apoptosis and platelet activation

Roger van Kruchten, Nadine J. A. Mattheij, Christine Saunders, Marion A. H. Feijge, Frauke Swieringa, Jef L. N. Wolfs, Peter W. Collins, Johan W. M. Heemskerk, Edouard M. Bevers

Blood (2013) 121 (10): 1850–1857.

https://doi.org/10.1182/blood-2012-09-454314

Published: 2013

Includes: Supplemental data

Journal Articles

Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight

Sven Björkman, MyungShin Oh, Gerald Spotts, Phillip Schroth, Sandor Fritsch, Bruce M. Ewenstein, Kathleen Casey, Kathelijn Fischer, Victor S. Blanchette, Peter W. Collins

Blood (2012) 119 (2): 612–618.

https://doi.org/10.1182/blood-2011-07-360594

Published: 2012

Includes: Supplemental data

Journal Articles

Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom

Charles R.M. Hay, Ben Palmer, Elizabeth Chalmers, Ri Liesner, Rhona Maclean, Savita Rangarajan, Michael Williams, Peter W. Collins, on behalf of United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO)

Blood (2011) 117 (23): 6367–6370.

https://doi.org/10.1182/blood-2010-09-308668

Published: 2011

Journal Articles

Compound heterozygosity for 2 novel TMEM16F mutations in a patient with Scott syndrome

Elisabetta Castoldi, Peter W. Collins, Patrick L. Williamson, Edouard M. Bevers

Blood (2011) 117 (16): 4399–4400.

https://doi.org/10.1182/blood-2011-01-332502

Published: 2011

Journal Articles

Inhibitor Eradication In Acquired Haemophilia A: Final Results of European Acquired Haemophilia Registry (EACH2)

Peter W Collins, Francesco Baudo, Paul Knoebl, Herve Levesque, Laszlo Nemes, Fabio Pellegrini, Lilian Tengborn, Angela Huth-Kuehne

Blood (2010) 116 (21): 715.

https://doi.org/10.1182/blood.V116.21.715.715

Published: 2010

Journal Articles

Management of Bleeding In Acquired Hemophilia: Results of the European Acquired Hemophilia Registry (EACH2)

Paul Knoebl, Francesco Baudo, Peter W Collins, Angela Huth-Kuehne, Herve Levesque, Pascual Marco, Laszlo Nemes, Fabio Pellegrini, Lilian Tengborn

Blood (2010) 116 (21): 716.

https://doi.org/10.1182/blood.V116.21.716.716

Published: 2010

Journal Articles

Acquired Haemophilia A and Pregnancy/Postpartum – a Report From a European Registry

Laszlo Nemes, Lilian Tengborn, Peter W Collins, Francesco Baudo, Angela Huth-Kuehne, Paul Knoebl, Pascual Marco, Herve Levesque

Blood (2010) 116 (21): 717.

https://doi.org/10.1182/blood.V116.21.717.717

Published: 2010

Journal Articles

Acquired Haemophilia: Clinical and Demographic Data.Results of European Acquired Haemophilia Registry (EACH2).

Pascual Marco, Peter W Collins, Paul Knoebl, Herve Levesque, Francesco Baudo, Laszlo Nemes, Lilian Tengborn, Angela Huth-Kuehne, Fabio Pellegrini

Blood (2010) 116 (21): 1398.

https://doi.org/10.1182/blood.V116.21.1398.1398

Published: 2010

Journal Articles

Use of a Population Pharmacokinetic Model of ADVATE In Pediatric and Adult Patients with Hemophilia A Permits Limited Blood Sampling for Individual Dose Tailoring.

MyungShin Oh, Sven Björkman, Phillip Schroth, Sandor Fritsch, Peter W Collins, Kathelijn Fischer, Victor S. Blanchette, Kathleen M. Casey, Gerald Spotts, Bruce M. Ewenstein

Blood (2010) 116 (21): 1416.

https://doi.org/10.1182/blood.V116.21.1416.1416

Published: 2010

Journal Articles

A novel deletion mutation is recurrent in von Willebrand disease types 1 and 3

Megan S. Sutherland, Anthony M. Cumming, Mackenzie Bowman, Paula H. B. Bolton-Maggs, Derrick J. Bowen, Peter W. Collins, Charles R. M. Hay, Andrew M. Will, Stephen Keeney

Blood (2009) 114 (5): 1091–1098.

https://doi.org/10.1182/blood-2008-08-173278

Published: 2009

Journal Articles

Clinical Implications of Pharmacokinetic Variables in the Management of Patients with Severe Hemophilia A.

Peter W. Collins, MD, Victor Blanchette, MD, Kathelijn Fischer, MD, Jan Astermark, MD, Phillip Schroth, Sandor Fritsch, PhD, Bruce M. Ewenstein, MD, PhD

Blood (2006) 108 (11): 1041.

https://doi.org/10.1182/blood.V108.11.1041.1041

Published: 2006

NARROW

Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously-Treated Patients with Hemophilia B: Results from an Extension Trial

Systematic Review of the Published Evidence on the Pharmacokinetic Characteristics of Factor VIII and IX Concentrates

Towards Successful Implementation of Pharmacokinetic-Guided Prophylactic Dosing of Clotting Factor Concentrate in Hemophilia; The Do’s and Don’ts after Discrete Choice Experiment Analysis

Modeling Minimally-Effective FVIII Trough Levels in Hemophilia a Patients on PK-Guided Prophylaxis

Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011

Fibrin-based clot formation as an early and rapid biomarker for progression of postpartum hemorrhage: a prospective study

Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects

Both TMEM16F-dependent and TMEM16F-independent pathways contribute to phosphatidylserine exposure in platelet apoptosis and platelet activation

Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight

Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom

Compound heterozygosity for 2 novel TMEM16F mutations in a patient with Scott syndrome

Inhibitor Eradication In Acquired Haemophilia A: Final Results of European Acquired Haemophilia Registry (EACH2)

Management of Bleeding In Acquired Hemophilia: Results of the European Acquired Hemophilia Registry (EACH2)

Acquired Haemophilia A and Pregnancy/Postpartum – a Report From a European Registry

Acquired Haemophilia: Clinical and Demographic Data.Results of European Acquired Haemophilia Registry (EACH2).

Use of a Population Pharmacokinetic Model of ADVATE In Pediatric and Adult Patients with Hemophilia A Permits Limited Blood Sampling for Individual Dose Tailoring.

A novel deletion mutation is recurrent in von Willebrand disease types 1 and 3

Clinical Implications of Pharmacokinetic Variables in the Management of Patients with Severe Hemophilia A.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only